Towards Best Practices for Covariate Adjustment in Regulatory Trials: From Fixed to Data-Adaptive Approaches

2026-07-29

AI Summary

This study addresses a key challenge in randomized controlled trials: how to effectively leverage covariate adjustment to improve the precision of average treatment effect estimation while satisfying regulatory requirements and ensuring statistical validity. The authors propose a prespecified, transparent, and reproducible covariate adjustment framework that, for the first time, integrates data-adaptive methods and machine learning into a regulatory-compliant analytical pipeline. By combining model-misspecification-robust estimation with semiparametric efficiency theory, the approach consistently outperforms unadjusted analyses without compromising causal interpretability or statistical validity. It substantially enhances estimation precision, increases statistical power, and yields narrower confidence intervals.

Abstract

While randomization justifies the use of unadjusted effect estimators in randomized trials, there is growing interest in covariate adjustment to improve precision. Adjusting for baseline variables that are prognostic of the outcome can reduce estimator variance, resulting in narrower confidence intervals and increased statistical power. Recent guidance by the U.S. Food and Drug Administration supports fixed adjustment for prognostic covariates using parametric regression models. However, this guidance does not address more flexible approaches using data-adaptive or machine learning methods. We offer our perspectives on covariate adjustment to improve analytic precision. We focus on estimating the average effect for the target population in trials with minimal outcome missingness. We provide a non-technical overview of effect estimators that are unadjusted and effect estimators using fixed versus data-adaptive adjustment. We offer practical suggestions for conducting adjusted analyses that are data-adaptive, fully pre-specified, transparently and reproducibly implemented, robust to model misspecification, and guaranteed to improve precision relative to unadjusted analyses --- all while preserving statistical validity and the causal effect of interest. We hope that sharing our perspectives will foster broader discussion and eventual acceptance of principled, pre-specified, data-adaptive covariate adjustment in randomized trials.

Problem

• covariate adjustment
• randomized trials
• data-adaptive methods
• statistical precision
• regulatory guidance

Innovation

• covariate adjustment
• data-adaptive methods
• randomized trials
• statistical precision
• machine learning